

Specialised Therapeutics Appoints New Logistics Partner

Singapore, 4 July 2022: International biopharmaceutical company Specialised Therapeutics (ST) has struck an important agreement with highly recognised logistics partner Healthcare Logistics (HCL) to store and distribute its growing portfolio of specialist healthcare products in Australia.

Under the terms of the arrangement, HCL will undertake all critical logistics functions on behalf of ST, including receipt of pharmaceutical products from ST's international pharmaceutical partners, storage and delivery Australia wide. It will also assist ST with secondary packaging of our products, as well as preparing and delivering clinical trial supplies to key hospitals, pharmacies and wholesalers at sites around Australia and New Zealand.

Commercial terms are not being disclosed, but the arrangement formally takes effect from today.

ST Chief Executive Officer Mr. Carlo Montagner said HCL was carefully and strategically selected for its high standards, state-of-the-art warehousing facilities and successful track record handling complex pharmaceutical products. He said the latest agreement was an extension of an existing alliance ST has with HCL in New Zealand.

“We have already been impressed by HCL's customer service and solutions focus in New Zealand,” Mr Montagner said. “The extension of this arrangement in Australia further cements our business partnership internationally.”

“As a business, we know HCL is well-versed in the complexities of managing specialty pharmaceutical products.”

“In addition, it is very clear that HCL prioritises the patient - the ultimate recipient of our stored therapies. We are confident this new arrangement will ensure that our medicines are delivered safely and efficiently, so patients are able to access products in a timely fashion - even with a 'same day' or 'next day' order.”

HCL is part of EBOS Group, which is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. EBOS is also a leading marketer and distributor of recognised animal care brands.

HCL Australia Executive General Manager Bradley James said the company was thrilled to build on its valued partnership with Specialised Therapeutics.

“Building strong relationships underpinned by our high-quality standards are at the core of everything we do, and we feel privileged that Specialised Therapeutics has again entrusted us to provide crucial storage and distribution support for their products,” he said.

“Our investment in a new warehouse in Sydney is a prime example of how we strive to deliver leading storage and logistics capability for our clients and meet their expanding needs.”

Ends.

About Specialised Therapeutics

Headquartered in Singapore, Specialised Therapeutics (ST) is an international biopharmaceutical company providing new specialist therapies and technologies to patients throughout Southeast Asia, as well as in Australia and New Zealand. ST and its regional affiliates collaborate with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life-changing healthcare solutions to patients affected by a range of diseases. Its mission is to provide therapies where there is an unmet need. The company’s broad therapeutic portfolio currently includes novel agents in oncology, haematology, neurology, ophthalmology and supportive care.

Additional information can be found at www.stbiopharma.com

About EBOS Group

EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care brand owner, product marketer and distributor.

Further Enquiries:

Emma Power, Corporate Affairs and Communications Manager, Specialised Therapeutics Asia +65 3158 9940 or +61 419 149 525 or epower@stbiopharma.com